Sutent® proactively antagonizes the metastatic problems with proliferative renal cell, gastrointestinal stromal cell and pancreatic neuroendocrine cell.1 Approved by FDA and with recommendation by NICE(UK) guideline2, Sutent® has been enlisted as subsidized medical treatment against two specific diseases by the Community Care Fund.3
- Sutent® (sunitinib malate) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version May 2015.
- National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 169. March 2009.
- Items supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.